TET-DNMT-ASXL1-OGT axis and clonal hematopoiesis in cancer and aging
Official title: The TET-DNMT-ASXL1-OGT axis: relevance to clonal hematopoiesis, heterochromatin integrity and cancer
Funded at La Jolla Institute for Immunology · NIH-11415065 · Data updated 2026-11-12
A long-running NIH project is exploring how specific gene mutations alter blood cell development and contribute to cancer, aging, and inflammation in people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | La Jolla Institute for Immunology NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 1, 2016 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $1,098,000 |
| NIH project number | 5R35CA210043-10 |
| Project ID | NIH-11415065 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals at risk for clonal hematopoiesis or related hematologic cancers, or those with age-related clonal mutations.
✕Less likely to help
People without risk factors for CH or with non-hematologic cancers may not directly benefit from this research.
What this research studies
If you have a condition linked to age-related blood disorders or cancer risk, this project could help explain how mutations in certain hematopoietic genes drive clonal expansions and genomic instability. Researchers will study how TET2, DNMT3A, and ASXL1 mutations affect DNA methylation and chromatin structure, and how these changes may lead to disease. The work uses advanced genetic tools to map molecular changes in blood-forming cells and their consequences for inflammation and cancer development. Findings could point to new targets for therapies that stabilize the genome and reduce disease progression.
Why it matters
Potential benefit: Greater understanding of the molecular drivers of clonal hematopoiesis and cancer, potentially informing future therapies.
How similar studies have gone: Previous work has linked chromatin changes and methylation to disease severity; this project extends those findings with a comprehensive mechanistic approach.
Where this research is happening
-
La Jolla Institute for Immunology
La Jolla, United States Active
Researchers
- Principal investigator: Rao, Anjana — La Jolla Institute for Immunology
- Study coordinator: Rao, Anjana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.